Management of small cell cancer of the lung

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) accounts for 20% to 25% of bronchogenic carcinoma cases. Combination chemotherapy offers the best chance for improved survival. Cisplatin plus etoposide appears to be the most reasonable choice for first line therapy. Increasing dose intensity, although sometimes associated with higher response rates, does not appear to significantly improve survival. Concurrent thoracic radiotherapy administered early in the course of chemotherapy confers a survival advantage over chemotherapy alone in limited-stage SCLC. Prophylactic cranial irradiation reduces central nervous system recurrences with minimal long-term sequelae and appears to improve survival. Several new cytotoxic agents are active in SCLC. These include gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan, and JM216. Novel approaches being investigated include antibodies to factors expressed by SCLC cells and agents targeting angiogenesis, cell cycle regulation, and cell-signaling pathways. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish (US)
Pages (from-to)384-390
Number of pages7
JournalCurrent Opinion in Pulmonary Medicine
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Small Cell Lung Carcinoma
irinotecan
docetaxel
gemcitabine
Cranial Irradiation
Topotecan
Drug Therapy
Bronchogenic Carcinoma
Cytotoxins
Etoposide
Paclitaxel
Combination Drug Therapy
Cisplatin
Cell Cycle
Radiotherapy
Thorax
Central Nervous System
Recurrence
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Management of small cell cancer of the lung. / Adjei, Alex.

In: Current Opinion in Pulmonary Medicine, Vol. 6, No. 4, 01.01.2000, p. 384-390.

Research output: Contribution to journalReview article

@article{da7c8b3c0f3a4750b4ccb37ed3205a3d,
title = "Management of small cell cancer of the lung",
abstract = "Small cell lung cancer (SCLC) accounts for 20{\%} to 25{\%} of bronchogenic carcinoma cases. Combination chemotherapy offers the best chance for improved survival. Cisplatin plus etoposide appears to be the most reasonable choice for first line therapy. Increasing dose intensity, although sometimes associated with higher response rates, does not appear to significantly improve survival. Concurrent thoracic radiotherapy administered early in the course of chemotherapy confers a survival advantage over chemotherapy alone in limited-stage SCLC. Prophylactic cranial irradiation reduces central nervous system recurrences with minimal long-term sequelae and appears to improve survival. Several new cytotoxic agents are active in SCLC. These include gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan, and JM216. Novel approaches being investigated include antibodies to factors expressed by SCLC cells and agents targeting angiogenesis, cell cycle regulation, and cell-signaling pathways. (C) 2000 Lippincott Williams and Wilkins, Inc.",
author = "Alex Adjei",
year = "2000",
month = "1",
day = "1",
doi = "10.1097/00063198-200007000-00022",
language = "English (US)",
volume = "6",
pages = "384--390",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Management of small cell cancer of the lung

AU - Adjei, Alex

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Small cell lung cancer (SCLC) accounts for 20% to 25% of bronchogenic carcinoma cases. Combination chemotherapy offers the best chance for improved survival. Cisplatin plus etoposide appears to be the most reasonable choice for first line therapy. Increasing dose intensity, although sometimes associated with higher response rates, does not appear to significantly improve survival. Concurrent thoracic radiotherapy administered early in the course of chemotherapy confers a survival advantage over chemotherapy alone in limited-stage SCLC. Prophylactic cranial irradiation reduces central nervous system recurrences with minimal long-term sequelae and appears to improve survival. Several new cytotoxic agents are active in SCLC. These include gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan, and JM216. Novel approaches being investigated include antibodies to factors expressed by SCLC cells and agents targeting angiogenesis, cell cycle regulation, and cell-signaling pathways. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - Small cell lung cancer (SCLC) accounts for 20% to 25% of bronchogenic carcinoma cases. Combination chemotherapy offers the best chance for improved survival. Cisplatin plus etoposide appears to be the most reasonable choice for first line therapy. Increasing dose intensity, although sometimes associated with higher response rates, does not appear to significantly improve survival. Concurrent thoracic radiotherapy administered early in the course of chemotherapy confers a survival advantage over chemotherapy alone in limited-stage SCLC. Prophylactic cranial irradiation reduces central nervous system recurrences with minimal long-term sequelae and appears to improve survival. Several new cytotoxic agents are active in SCLC. These include gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan, and JM216. Novel approaches being investigated include antibodies to factors expressed by SCLC cells and agents targeting angiogenesis, cell cycle regulation, and cell-signaling pathways. (C) 2000 Lippincott Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033914072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033914072&partnerID=8YFLogxK

U2 - 10.1097/00063198-200007000-00022

DO - 10.1097/00063198-200007000-00022

M3 - Review article

C2 - 10912650

AN - SCOPUS:0033914072

VL - 6

SP - 384

EP - 390

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 4

ER -